机译:口腔抗凝血剂,以防止CKD阶段5D患者非衰弱性心房颤动:NKF-KDOQI争议报告
Division of Nephrology and Hypertension Department of Medicine Loyola University Chicago;
Division of Cardiology Department of Medicine Hennepin County Medical Center University of;
Division of Nephrology Department of Medicine Tufts Medical Center;
Division of Nephrology Department of Medicine Johns Hopkins Medical Institutions;
Division of Nephrology Department of Medicine University of California at San Diego;
Division of Nephrology Department of Medicine Johns Hopkins Medical Institutions;
Division of Nephrology Department of Medicine Wake Forest University Medical Center;
Division of Nephrology and Hypertension Department of Medicine Loyola University Chicago;
机译:口腔抗凝血剂,以防止CKD第5D阶段患者非血清心房颤动的卒中:NKF-KDOQI争议报告(第70卷,PG 859,2017)
机译:口腔抗凝血剂,以防止CKD阶段5D患者非衰弱性心房颤动:NKF-KDOQI争议报告
机译:口腔抗凝血剂,以防止CKD阶段5D患者非衰弱性心房颤动:NKF-KDOQI争议报告
机译:心房颤动患者的口腔抗凝血剂自我管理:它有多效益和安全?
机译:达比加群与华法林预防慢性非瓣膜性房颤患者的中风。
机译:直接口服抗凝剂:预防非瓣膜性房颤患者中风的关键考虑因素
机译:口腔抗凝血剂与抗血小板治疗预防患者患者患者,患者患者患者,没有中风或短暂性缺血性发作